
Inhaled corticosteroid is *not* associated with a poor prognosis in COVID-19




Study population: 6,520 confirmed COVID-19 patients in South Korea

Non-ICS user (n=6,335)

Mortality (3.1%)





mCCI = modified Charlson Comorbidity Index (scores excluding asthma or COPD), SES = socioeconomic status, ICS = inhaled corticosteroid, LABA = long-acting β2 agonist

- ICS group showed higher mortality than non-ICS group in COVID-19.
- The use of ICS (\pm LABA) was not associated with mortality after adjusted confounding factors (OR = 1.40, 95% CI (0.76-2.60), p = 0.28)

